| Literature DB >> 33174958 |
Leandro Augusto Ledesma1, Elba Regina Sampaio Lemos2, Marco Aurélio Horta3.
Abstract
INTRODUCTION: Rabies is a major and seriously neglected public health problem worldwide. A treatment consisting of supportive therapy with the use of drugs that show antiviral activity is called the Milwaukee Protocol. In Brazil, this protocol was adapted to the national reality and called the Recife Protocol. In this study, we compared the Milwaukee Protocol with the Recife Protocol, assessing the differences and how these differences may change the course of clinical management.Entities:
Year: 2020 PMID: 33174958 PMCID: PMC7670764 DOI: 10.1590/0037-8682-0352-2020
Source DB: PubMed Journal: Rev Soc Bras Med Trop ISSN: 0037-8682 Impact factor: 1.581
Comparison of Milwaukee and Recife clinical protocols in the treatment of human rabies, from 2004 to 2019.
| Clinical feature | Milwaukee | Recife |
|---|---|---|
| Vaccine or immunoglobulin | Not recommended | Not recommended |
| Isolation | Recommended | Recommended |
| Sedative for aggressiveness | Recommended | Ramsey IV |
| Sedation withdrawal | Initiate progressive withdrawal after D8*-complete on D12 | After 3-5 IU/mL** antibody titers in CSF |
| Hyponatremia | Attention to D5-D8: Cerebral salt wasting (CSW) | To evaluate diagnoses of SCPS*** and syndrome of inappropriate antidiuretic hormone secretion |
| Hypernatremia | No recommendations | Treating causes: Dehydration or diabetes insipidus |
| Glycemic control | Insulin dripping use | Insulin as needed |
| Diuresis | 0.5 mL/(kg∙h) | 0.5 mL/(kg∙h) |
| Temperature | 35-37 °C | 35-37 °C |
| Medications | ||
| Ketamine | Recommended | Recommended |
| Midazolam | Recommended | Recommended |
| Fentanyl | Contraindicated | Not Recommended |
| Haloperidol to improve sedation | Recommended | - |
| Amantadine | Recommended | Recommended |
| Vitamin C | Indicated 250 mg-500 g IV/day | indicated 1 g IV/day |
| Sapropterin or Biopterin | Sapropterin 5mg/(kg∙day) | Biopterin 8 mg/kg IV 8/8h |
| Fludrocortisone or Hydrocortisone | Recommended | Recommended |
| Complementary exams | ||
| Serum Na+ dosage | Twice a day | Twice a day |
| Serum Mg++ dosage | Daily between D5 and D8 and D12 and D15 | Daily |
| Serum zinc | Weekly | Weekly |
| Nuclear magnetic resonance | Recommended | Recommended |
| Transcranial Doppler | Daily | Daily |
| Eyes ultrasound | Daily | No comments |
| Virology and antibodies | ||
| Saliva RT-PCR/PCR | Daily | Daily |
| Serology | Daily until D14; after D14, once or twice a week | Twice a week |
| Cerebral spinal fluid antibodies | Twice a week | Weekly |
| Spinal cerebral fluid | Cellularity and biochemistry twice a week | No comments |
| Tetrahydrobiopterin dosage (2mg/Kg/day) | Did not comment | 15 after confirmation + another dosage 15 days after full dose replacement |
*D1-D15: day 1, day 2, etc. **International Units/mL. ***Salt-losing brain syndrome.
Survival of patients with human rabies treated with Milwaukee Protocol, from 2004 to 2019.
| Sex | Age | Animal | T1 | T2 | Outcome | T3 | Year | Country | M1 | M2 | M3 | Induced coma | Virus | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 15 | - | - | 3 | Death | 26 | 2015 | India | 9 | 1 | 2 | 1 | No information available |
|
| M | 33 | Dog | 8 | 5 | Death | 8 | 2008 | Canada | 2 | 1 | 1 | 1 | No information available |
|
| M | 16 | Bat | 6 | 5 | Death | 7 | 2006 | US (TX) | 1 | 1 | 2 | 1 | No information available |
|
| F | 10 | Bat | 16 | 12 | Death | 15 | 2010 | US (IND) | 1 | 1 | 1 | 1 |
|
|
| M | 11 | Dog | 104 | 2 | Death | 27 | 2006 | US (CA) | 1 | 1 | 1 | 1 | No information available |
|
| M | 73 | Bat | 24 | 15 | Death | 64 | 2007 | Canada | 1 | 1 | 1 | 1 | No information available |
|
| M | 55 | Dog | 6 | 8** | Death | - | 2009 | Germany | 1 | 1 | 2 | 1 | No information available |
|
| F | 34 | Bat | 3.5 | 6 | Death | 20 | 2007 | Netherlands | 1 | 1 | 1 | 1 |
|
|
| M | 5 | Dog | 5 | 5 | Death | 22 | 2007 | Eq. Guinea | 1 | 1 | 1 | 1 | Gabon canine rabies type virus |
|
| M | 55 | Bat | 6 | 14*** | Death | 15 | 2009 | US (MS) | 1 | 1 | 2 | 1 | No information available |
|
| F | 9 | Cat | 4 | 6 | Death | 75 | 2015 | Colombia | 1 | 1 | 1 | 1 | RABVs associated with vampire bats in Colombia |
|
| M | 15 | Bat | 20 | 17 | Death | 16 | 2009 | Colombia | 1 | 1 | 1 | 1 | RABV associated with the tricolor bat ( |
|
| F | 37 | Dog | 96 | 10 | Death | 35 | 2010 | UK | 1 | 1 | 1 | 1 | RABV variant found in Hematophagous bat |
|
| M | 42 | Dog | - | 7 | Death | 24 | 2009 | US (VA) | 9 | 9 | 9 | 9 | No information available |
|
| F | 11 | Cat | 6 | 2 | Death | - | 2010 | Romania | 1 | 1 | 1 | 1 | RABV found in Southeast Romania |
|
| F | 41 | Dog | 11 | 6 | Death | 15 | 2012 | Portugal | 1 | 1 | 2 | 1 | RABV lineage Africa 2 crane B |
|
| M | 24 | Dog | 28 | 7 | Death | 17 | 2011 | US (NY) | 9 | 1 | 2 | 1 | Canine RABV found in Afghanistan |
|
| M | 63 | Dog | 12 | 7 | Death | 30 | 2011 | US (MA) | 9 | 1 | 2 | 1 | RABV associated with bat motes (eared) |
|
| M | 9 | Monkey | 5 | 18 | Death | 7 | 2011 | BR (CE) | 1 | 1 | 2 | 1 | No information available |
|
| M | 29 | Dog | - | 25 | Death | 35 | 2011 | RSA | 9 | 1 | 1 | 9 | No information available |
|
| M | 32 | Dog | 12 | 2 | Death | 14 | 2011 | India | 1 | 1 | 1 | 1 | No information available |
|
| M | 40 | Dog | 3.5 | 11 | Death | 22 | 2012 | Italy | 2 | 2 | 2 | 2 | Arctic-like 1 lineage of the rabies virus (RABV) circulating in southern Asia, northern India, and the Middle East |
|
| M | 41 | Dog | - | - | Death | 99 | 2012 | Canada | 9 | 9 | 9 | 9 | RABV from the island of Hispaniola |
|
| F | 58 | Dog | 36 | 4 | Death | 10 | 2014 | UK | 1 | 1 | 2 | 1 | No information available |
|
| M | 28 | Dog | - | 11 | Death | 22 | 2013 | US (TX) | 1 | 1 | 2 | 1 | No information available |
|
| M | 30 | Dog | 16 | 2 | Death | 36 | 2013 | China | 9 | 9 | 9 | 9 | No information available |
|
| M | 23 | Dog | 16 | 3 | Death | 11 | 2015 | India | 1 | 1 | 2 | 1 | No information available |
|
| M | 12 | Dog | 38 | - | Death | 13 | 2019 | Saudi Arabia | 9 | 9 | 9 | 1 | No information available |
|
| F | 15 | Bat | 4 | 5 | S1 | 76 | 2004 | US (WI) | 1 | 1 | 1 | 1 | No information available |
|
| M | 15 | Bat | 4 | 7 | S2 | 100 | 2008 | Brazil (PE) | 1 | 1 | 2 | 1 | No information available |
|
| F | 17 | Bat | 11 | 18 | S1 | 34 | 2010 | US (TX) | 2 | 2 | 2 | 2 | No information available |
|
| M | 4 | Dog | 3 | - | S3 | 50 | 2016 | India | 2 | 2 | 2 | 1 | No information available |
|
| F | 17 | Dog | 3 | 13 | S1 | 90 | 2011 | India | 1 | 1 | 1 | 1 | No information available |
|
| F | 8 | Cat | - | 9 | S1 | 36 | 2011 | US (CA) | 1 | 1 | 2 | 1 | No information available |
|
| M | 4 | Dog | 23 | - | S3 | 90 | 2012 | RSA | 2 | 2 | 2 | 2 | No information available |
|
| M | 13 | Dog | 5 | - | S3 | - | 2014 | India | 2 | 2 | 2 | 1 | No information available |
|
| M | 6 | Dog | 3 | - | S3 | - | 2015 | India | 2 | 2 | 2 | 1 | No information available |
|
| M | 14 | Bat | - | - | S1 | 40 | 2018 | Brazil (AM) | 1 | 1 | 1 | 1 | No information available |
|
| M | 8 | Dog | 20 | 8 | S2 | 90 | 2019 | India | 9 | 9 | 9 | 9 | No information available |
|
1: used; 2: not used; 9: no information; T1 - incubation period; T2 - Time between onset of symptoms and initiation of treatment protocol (days); T3 - Time elapsed between hospitalization and death or hospital discharge (days); S1 - Survivor with few sequelae; S2 - Survivor with moderate sequelae; S3 - Survivor with severe sequelae; M1 - Amantadine; M2 - Ketamine; M3 - Ribavirin; **Vaccination performed one day before hospitalization. ***Protocol not initiated due to severity of neurological condition